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NEOSTIGMINE
Abstract

Background/Significance: A large population of patients entering the post-operative anesthesia
care unit (PACU) with residual neuromuscular blockade (NMB), as defined by a Train-of-Four
ratio < 0.9, has been reported in the literature. Patients with residual NMB have a higher
likelihood of respiratory insufficiency and failure, and many others experience uncomfortable
feelings of muscle weakness. Neostigmine is a commonly used agent to reverse NMB, but little
is known about factors which affect use and dosing.
Purpose/Objectives: The purpose of this Scholarly Leadership Project was to identify the
factors being considered by anesthesia providers when using neostigmine as a reversal agent for
NMB. The findings from this study and current evidence were utilized in the formulation of a set
of evidence-based practice guidelines for the reversal of NMB with neostigmine.
Design: This study utilized a descriptive, online survey design.
Methods: A survey was sent through the email LISTSERV of the Illinois Association of Nurse
Anesthetists (IANA), the official professional organization of certified registered nurse
anesthetists (CRNAs) in the state of Illinois.192 active CRNA members of the IANA
participated. A validated, investigator-developed online survey, which examined the factors
being considered by anesthesia providers when using neostigmine, was sent to 1,384 members of
the IANA.
Analysis: Descriptive statistics using means, standard deviation, frequencies, and percentages
was used to describe the sociodemographics of respondents and the online responses to the
survey. Chi square statistics were utilized to examine different factors considered by CRNAs
when administering neostigmine.
Findings: This study revealed different factors that anesthesia providers consider when using
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neostigmine including: quantity and quality of muscle twitches present during train-of-four
monitoring, twitches with and without fade, and time elapsed since the last dose of
neuromuscular blocking agent. Furthermore, no statistically significant differences were found
in the mean score of the factors being considered for neostigmine use between CRNAs in terms
of their years of experience, types of practice, institutional settings, and level of education.
Practice Implications: Project results provide an evidence-based practice protocol, which
anesthesia providers can use in discerning adequate and appropriate reversal of NMB.
Keywords: Neuromuscular blockade, neuromuscular blocking agents, neostigmine, residual,
reversal
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Section I: Introduction
Background and Significance
Non-depolarizing muscle relaxants (NDMR) are agents, which cause temporary
musculoskeletal paralysis through competitive inhibition of acetylcholine at the motor end plate
(Butterworth, Mackey, & Wasnick, 2013b). Intraoperative use of NDMRs allows for reliable,
reversible muscle relaxation, which facilitates surgical access to the operative site. Drugs that
reverse the effects of NDMRs are known as cholinesterase inhibitors (Kruidering-Hall &
Campbell, 2012). Cholinesterase inhibitors that are currently available include neostigmine,
edrophonium, pyridostigmine, and physiostigmine, with neostigmine and edrophonium being the
most commonly used in anesthesia practice in the United States. This study focused only on
neostigmine.
Neostigmine is a common agent used to reverse the effects of NDMRs through inhibition
of the enzyme, acetylcholinesterase (Butterworth, Mackey, & Wasnick, 2013a). Through
inhibition of acetylcholinesterase, acetylcholine (ACh) levels increase, which results in the
stimulation of both nicotinic and muscarinic receptors (Butterworth, Mackey, & Wasnick,
2013a). Nicotinic receptors are found in the neuromuscular junction of skeletal muscles and
increased stimulation of these receptors results in stronger contractions of muscle fibers
(Pappano, 2012). Conversely, muscarinic receptors are found in mucous membranes, lining of
the lungs, atrioventricular (AV) node of the heart, eyes, and central nervous system (Pappano,
2012). Stimulation of muscarinic receptors by ACh results in bradycardia, prolongation of the
QT interval, increased mucous secretion, bronchoconstriction, pupillary constriction, and smooth
muscle contraction of the intestines and bladder (Butterworth, Mackey, & Wasnick, 2013a).
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Glycopyrrolate, an anti-muscarinic agent, is routinely administered concomitantly with
neostigmine, which abates the side effects associated with muscarinic agonism (Butterworth,
Mackey, & Wasnick, 2013a).
Within the practice of anesthesia there is a wide variance in the dosing and administration
practices of neostigmine (Duvalestin, Cunin, Plaud, & Maison, 2008; Gray & Wilson, 1959;
Naguib et al., 2010; Videira & Vieira, 2011). Anesthesia providers often base dosing
preferences on several factors that include age, quality of muscle relaxation, timing of the last
administration of NDMR, disease processes affecting drug metabolism and excretion, such as
liver and kidney disease). Currently, there are no universally accepted guidelines for reversal of
neuromuscular blockade with neostigmine. Moreover, several published articles have called for
the development of a set of guidelines for NMB reversal based on the negative effects of residual
NMB (Cedborg et al., 2014; Saur, Stahn, Soltesz, Noeldge-Schomburg, & Mencke, 2011;
Sundman, et al., 2000). A synthesis of the adverse effects of residual NMB can be found in
Table 1.
Neuromuscular monitoring allows the anesthesia provider to assess the status of muscle
paralysis through electrical stimulation of nerve fibers. Train-of-four (TOF) neuromuscular
monitoring consists of four separate electrical impulses delivered at intervals of 0.5 seconds,
which in non-paralyzed will result in four brief muscle contractions, also known as twitches
(Dorsch & Dorsch, 2011). The number and intensity of twitches obtained is correlated to the
intensity of the neuromuscular block. Train-of-four ratio (TOFR) compares the amplitude of the
fourth muscle twitch divided by the amplitude of the first muscle twitch (Dorsch & Dorsch,
2011). A TOFR of 1 (100%) signifies the absence of NMB. Conversely, a lower TOFR
signifies a more intense NMB (Dorsch & Dorsch, 2011).
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According to Murphy and Brull (2010), 40% of postoperative patients whom received
intraoperative muscle relaxation have residual NMB with a train-of-four (TOF) ratio < 0.9 and 13% will experience an adverse event due to residual paralysis. A study by Debaene, Plaud, Dilly,
& Donati (2003) identified 45% of postoperative patients had residual neuromuscular blockade
after receiving a single dose of intermediate-acting NDMR. Cedborg et al. (2014) identified an
increased incidence of pharyngeal dysfunction in patients with partial NMB, resulting in
aspiration.
Problem Statement
A wide variation exists among anesthetists in the dosing and administration of NMB
reversal agents. Additionally, no universally published guidelines exist for the reversal of NMB.
As a result of the large variation in dosing and administration of NMB reversal agents, a
significant number of post-operative patients have residual NMB. Patients with residual NMB
may experience hypoventilation, leading to hypoxia, and possible apnea (Kruidering-Hall &
Campbell, 2012).
Study Purpose
This project identified the factors in which anesthesia providers currently use to dose and
administer neostigmine and examine the types of neuromuscular monitoring used by CRNAs
during the reversal of NMB using neostigmine. The findings from this study can aid in the
development of an evidence-based practice protocol for the reversal of NMB using neostigmine.
This study aimed to answer the following research questions:
1. What factors do anesthesia providers consider when administering neostigmine?
2. What are the significant factors that anesthesia providers use to determine neostigmine
dosing?
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3. What are the types of neuromuscular monitoring are used by anesthesia providers during
the reversal of NMB using neostigmine?
4. Are there significant differences in the factors considered by anesthesia providers
according to practice type (academic versus non-academic practice), years of experience
(less than 5 years versus 5 years of more), level of education (Bachelors versus Masters
versus Doctoral degree), and type of institution in which anesthesia is practiced.
Conceptual Framework
The conceptual basis for the development of an evidence-based practice (EBP) protocol
for safe NMB reversal and implementing the protocol into the practice of anesthesia providers is
consistent with the Stetler model of Evidence-based Practice. The model is grounded in the
conceptual framework of research utilization (RU), which according to Stetler (2001), “is the
process of transforming research knowledge into practice” (p. 282). Furthermore, RU dominates
the early steps of the Stetler model, and results in the acceptance of evidence-based practice
found in the latter stages of the model (Stetler, 2001).
The Stetler model of evidence-based practice, describes five phases of how practitioner
analyze and use study findings to implement evidence-based nursing practice change (Dang et al.,
2015). As described by Stetler (1994; 2001) the five phases are as follows:
Phase I: Preparation. During the preparation phase the practitioner defines the purpose
and outcomes for each issue (Stetler, 2001). In addition, influencing factors (i.e. internal,
external), which may interfere with research progress or validity, should be identified (Stetler,
2001). Furthermore, various sources of research evidence are collected and sorted.
Phase II: Validation. During the validation phase the practitioner evaluates evidence in
the form of a critique and synopsis (Stetler, 2001). Furthermore, sources are rated based on the
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strength of the findings (Stetler, 2001). If sufficient evidence exists the researcher moves into
phase III of the model (Stetler, 1994). Conversely, if there is insufficient evidence the study
ends at phase II (Stetler, 1994).
Phase III: Comparative evaluation/Decision making. During the comparative
evaluation or decision making phase the practitioner uses a set of four criteria to determine if
study findings can be applied to practice (Stetler, 1994). First, the “fit of setting” criterion
allows the researcher to investigate similarities between the sample and the study setting, and the
population and setting of which EBP is being implemented (Stetler, 2001). Second, the
“feasibility: r, r, r” criterion assesses the risk, resources, and readiness for implementation of
EBP (Stetler, 2001). Third, the “current practice” criterion assesses the effectiveness of current
practice and the relevance for EBP in the current practice (Stetler, 1994). Fourth, the
“substantiating evidence” criterion assesses the overall strength of the research evidence (Stetler,
2001). Evidence is then labeled as either “to not use,” “to use,” or “to consider use” (Stetler,
2001, p. 277). If the evidence is labeled “to use” or “to consider use” the pracitioner progresses
to phase IV, however if the evidence is labeled “to not use” the study is stopped (Stetler, 2001).
Phase IV: Translation/application. The translation or application phase focuses on the
integration of the developed EBP (Stetler, 2001). The research findings are converted into
practice change or recommendations (Dang et al., 2015).
Phase V: Evaluation. During the evaluation phase the pracitioner assesses the various
outcomes of the practice change (Stetler, 2001).
The use of a theoretical framework helped to guide planning and implementation stages
of the Scholarly Leadership Project. The Stetler model of evidence-based practice as developed
by Stetler (1994; 2001) enhances the strength of the evidence-based guidelines for
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neuromuscular blockade reversal using neostigmine by guiding the acquisition and application of
evidence. Phase V, evaluation, will not be conducted in this project, however evaluation of
protocol dissemination may be the focus of follow up studies.
Section II: Literature Review
A search of the literature regarding neostigmine dosing and administration, and the
incidence of neuromuscular blockade was conducted. The literature search was performed using
the following computerized databases: Web of Science, PubMed, and ScienceDirect. The
following Medical Subject Heading (MeSH) terms “ neuromuscular blockade” and “neostigmine”
plus common search term, "residual" were utilized during the computer-based literature search.
The search results were filtered by removing studies that contained the term “sugammadex” as
this NMB reversal agent lacked FDA approval at the time the literature review was written and is
not included in the subject of this study. The database search generated 290 articles. Journal
articles included in the literature review were scholarly papers meeting the following criteria:
demonstrated a knowledge deficit in the area of neuromuscular block (NMB) reversal; contained
information that is important in the creation of best practice guidelines and/or objectives aimed at
improving practice and patient outcomes.
Residual Neuromuscular Blockade
Incidence. Residual neuromuscular blockade is defined as a train-of-four ratio (TOFR) <
0.9. A study performed by Murphy et al. (2005) demonstrated that the vast majority of patients
(87.5%) have residual NMB immediately before tracheal extubation despite passing standard
methods of extubation criteria - TOF 4/4 without fade (incremental decrease in the amplitude of
each consecutive twitch), eye opening, adequate spontaneous ventilation, and five-second head
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lift or hand grasp. The findings of this study suggest that the standard methods of evaluating the
effectiveness of NMB reversal are ineffective in identifying residual NMB.
Several similar studies have demonstrated the presence of residual NMB, which
progressed into the postoperative phase of recovery. In a study by Gaszynski, Szlachcinski,
Jakubiak, and Gaszynski (2009), 48% of patients entering the post-anesthesia care unit (PACU)
had residual NMB (TOF Ratio <0.9). Furthermore, 26% of the patients had a TOF ratio less
than 0.7. Adamus, Koutna, and Neoral (2007) performed a study in which no neuromuscular
monitoring was used during the anesthetic. The study demonstrated a 34% incidence of residual
neuromuscular blockade upon arrival to the PACU. The researchers compared the patients with
postoperative residual NMB to those that had fully recovered; they discovered that the patients
with residual NMB received larger doses of rocuronium, given less neostigmine, and there was
less time between the last dose of rocuronium and the administration of neostigmine.
Sauer, Stahn, Soltesz, Noeldge-Schomburg, and Mencke (2011) conducted a study in
which one group received a standardized weight-based dose of neostigmine and the other
received a placebo. Patients who received neostigmine were allowed to return to a TOF ratio of
1.0 before tracheal extubation, whereas the placebo group were tracheal extubated at a TOF ratio
less than 1.0, but without fade in TOF and double-burst nerve stimulation. Double-burst
stimulation is a set of three electrical stimuli at 50 Hz followed by another set of two or three
electrical stimuli timed 0.75 seconds later. Fifty-percent of the placebo group developed
hypoxemia, compared to 28% in the neostigmine group. This study demonstrated that
neostigmine was effective in antagonizing rocuronium versus placebo, however a large
population of patients still developed adverse respiratory outcomes despite full reversal of NMB.
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Complications. The diaphragm is a skeletal muscle therefore NMBAs impair diaphragm
excursion. Impairment of diaphragm may result in shortness of breath, atelectasis (collapse of
alveoli resulting in intrapulmonary shunting), respiratory distress, or respiratory failure.
Furthermore, skeletal muscles are involved in swallowing, movement of the vocal cords,
epiglottis, and tongue, and for stenting open the structures of the upper airway (i.e.
laryngopharynx, oropharynx, and nasopharynx). For patients with neuromuscular paralysis the
anesthesia provider is tasked with controlling ventilation, and protecting the airway from
aspiration. Therefore it can be hypothesized that a patient with residual NMB may also require
airway management to maintain adequate ventilation and to prevent aspiration. In fact, a study
by Eikermann et al. (2007) demonstrated that patients with partial NMB have decreased upper
airway volumes during inspiration. Additionally, expiratory volume and respiratory rate were
not affected by partial NMB (Eikermann et al., 2007). In a similar study, Eriksson et al. (1997)
demonstrated that patients with partial neuromuscular paralysis had a higher likelihood of
aspiration due to pharyngeal dysfunction if the TOFR was less than 0.9. In fact, six out of 14
volunteers aspirated with a TOFR less than 0.9, while no volunteers aspirated with a TOFR
greater than 0.9 (Eriksson et al., 1997).
Cedborg et al. (2014) performed a study involving elderly patients with partial
neuromuscular paralysis and the inability to protect their airway from aspiration. They
concluded that partial neuromuscular paralysis increases pharyngeal dysfunction with aspiration
from 37% (control) to 71% (study). A similar study by Sundman et al. (2000) compared the
incidence of pharyngeal dysfunction in a control group with patient with partial neuromuscular
paralysis at TOFR 0.6, 0.7, 0.8 and 0.9. The control group had a pharyngeal dysfunction rate of
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6% compared to 28% at a TOFR of 0.6; 17% at a TOFR of 0.7; 20% at a TOFR of 0.8; and 13%
for patients with a TOFR greater than 0.9 (Sundman et al., 2000).
Neostigmine
Administration. Studies have demonstrated that the majority of anesthesia providers do
not routinely reverse NMB (Naguib et al., 2010; Osmer, Vogele, Zickman, & Hempelman, 1996).
However current studies recommend the routine reversal of NMB (Miller & Ward, 2010;
Kopman & Eikermann, 2009). However, if objective neuromuscular monitoring can
demonstrate a TOFR ≥ 0.9 neostigmine is not reccomended, nor is it required (Lien, 2010).
When administrating neostigmine to reverse NMB the goal is to time the dose of the
reversal agent so that the peak effect of the drug occurs closely before tracheal extubation.
Buder et al. (2010) concluded that a reduced dose of neostigmine adequately reverses a shallow
NMB (TOFR > 0.4) caused by atracurium within 10 minutes. Murphy (2006) suggests
practitioners are administering the reversal agent too late and thus not allowing sufficient time
for the reversal agent to act. Furthermore, full reversal of an intense NMB may require 20-30
minutes, and thus Brull & Murphy (2010) recommends reversal be given 15-30 minutes before
tracheal extubation.
Dosing. The standard dosing of neostigmine when reversing NMB is 25-75 mcg/kg
(Nagelhout, 2014). A study by Buder et al. (2010) evaluated the dose-effect relationship of
neostigmine. Results of the study determined the NMB recovery time from the start of the
neostigmine administration to a TOFR of 0.9 and 1.0 with starting TOFR of 0.4 and 0.6 (Buder,
2010). NMB recovery time for a starting TOFR of 0.4 to an end point of TOFR 0.9 are as
follows: six minutes for a neostigmine dose of 10 mcg/kg, six minutes for a neostigmine dose of
20 mcg/kg, and four minutes for a neostigmine dose of 30 mcg/kg (Buder, 2010). NMB
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recovery time for a starting TOFR of 0.6 to an end point of TOFR 0.9 are as follows: four
minutes for a neostigmine dose of 10 mcg/kg, three minutes for a neostigmine dose of 20 mcg/kg,
and four minutes for a neostigmine dose of 30 mcg/kg (Buder, 2010). Furthermore, the
probability of successful reversal within 10 minutes of neostigmine administration increased as
the dosage increased with 30 mcg/kg near 100% at TOFR of 0.4 and 0.6 (Buder, 2010). These
results suggest that moderate degrees of NMB may be adequately antagonized with neostigmine
dosages of 20 – 30 mcg/kg. There is a lack of research for a dose-effect relationship at higher
intensity of NMB.
Age. It is a well known that pharmacokinetics and pharmacodynamics vary significantly
across the age spectrum and should be given special consideration when dosing neostigmine. A
study by Bevan et al. (1999) demonstrated significant variation between adults, aged 20-65 years
old, and children, aged 2-12 years old, in the recovery time from NMB after reversal with
neostigmine. Children with NMB due to rocuronium administration recovered to a TOFR of 0.9
in 12.1 minutes versus adults who recovered in 37.1 minutes when neostigmine is administered
five minutes after relaxant (Bevan et al., 1999). However, when neostigmine is administered
with a TOFR of 0.25, children recovered from NMB from rocuronium in 4.8 minutes versus
adults who recovered in 4.5 minutes (Bevan et al., 1999). This study demonstrates that age is an
important factor when reversing an intense NMB as evidenced by the large age group variation
in time when neostigmine was administered five minutes after NDMR. However, if reversing
when a TOFR is ≤ 0.25 it seems age becomes less of a factor.
Body Composition. Studies have shown that obesity increases the duration of NMB
(Schwartz, Matteo, Ornstein, & Halevy, 1992; Weinstein et al., 1988). As a result of these study
conclusions, it could be hypothesized that obesity also affects the reversal of NMB. In fact, a
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study by Suzuki, Masaki, & Ogawa (2006) demonstrated that obese patients with NMB reversed
by neostigmine required a significantly longer time to reach a TOFR of 0.9 in comparison with
the normal weight and overweight patient populations. In fact, obese patients required 25.9
minutes to obtain a TOFR of 0.9, whereas overweight patients required 14.6 minutes and normal
weight patients required only 6.9 minutes (Suzuki, Masaki, & Ogawa, 2006). The results from
this study demonstrate that the obese patient requires a significantly longer time to recover from
NMB and thus the anesthesia provider should consider early administration of neostigmine.
Monitoring
Neuromuscular monitoring is essential for effective reversal of NMB. Without the use of
monitoring the anesthesia provider is blindly administering additional muscle relaxant and
reversal agent. Despite the importance of neuromuscular monitoring several studies have
demonstrated that a large number of anesthesia practitioners do not routinely use neuromuscular
monitoring in their practice (Grayling & Sweeney, 2007; Sorgenfrei, Mogensen & Swiatek,
2005; Buder et al, 2003). Brull and Murphy (2010) assert, “perioperative monitoring of evoked
neuromuscular responses that guides the administration of anticholinesterases and documents
return of neuromuscular function should be a standard of care” (p. 135).
Qualitative or subjective nerve monitoring uses an electrical impulse to stimulate an
evoked potential along a peripheral motor nerve, which results in a brief contraction or twitch of
the muscle that the nerve innervates. The anesthesia provider observes the muscle twitch and
notes the quality (fade versus no-fade) and the quantity (twitch count). Peripheral nerves
commonly used for twitch monitoring include the facial, ulnar, and tibial nerves, however
reliability of twitch monitoring varies amongst the nerves. Thilen et al. (2012) concluded that
train-of-four nerve monitoring of the facial nerve was associated with a higher incidence of
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residual neuromuscular block when compared to nerve monitoring at the ulnar nerve (incident

rate of 52% versus 22% respectively). Thus, the ulnar nerve is the preferred site for qualitative
(subjective) nerve monitoring.
Monitoring of clinical signs is a common method used by practitioners to assess for
residual NMB. These clinical signs include patient responsiveness, subjective measurements of
muscle strength (i.e. 5-second head lift, hand grasp), eye opening, and tongue extrusion, however
studies have demonstrated these tests do not reliably predict adequate reversal of neuromuscular
blockade (Eikermann, Groeben, Hussing, & Peters, 2003; Hayes, Mirakhur, Breslin, Reid, &
McCourt, 2001; Fruergaard, Mogensen, Berg, & El Mahdy, 1998; Mogensen & Claudius, 2010).
According to Grayling & Sweeney (2007), the majority of anesthesia providers primarily rely on
clinical signs when assessing the status of neuromuscular blockade.
Section III: Methods
Design
This study utilized a descriptive, online survey design.
Setting
The online survey was distributed to all certified registered nurse anesthetists (CRNAs)
who are members of the Illinois Association of Nurse Anesthetists (IANA), the official
professional organization of CRNAs in the state of Illinois.
Sample
The sample for this study included CRNAs who are members of the IANA. Student
registered nurse anesthetists (SRNAs) were excluded from this study whether members of the
IANA or not. Additionally, anesthesiologists and anesthesia residents were excluded from the
survey by means of the survey distribution.
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Sample Size
There are approximately 1,384 CRNA members of the IANA. A convenience sampling
of the population described above was utilized in this study. Online surveys can have a wide
range of responsiveness. Based on a study by Cook, Health, and Thompson (2000), an average
30% response rate was found when 39 separate online surveys were analyzed (Pan, 2010).
Therefore, for this study the targeted response rate was 30%. The number of complete responses
was 192 (13.7%).
Recruitment Procedure
The subjects for this study were CRNAs recruited from the IANA. Institutional Review
Board (IRB) approval was obtained from DePaul University. A form letter was emailed to the
administrator of IANA requesting to send out the web link for the online Qualtrics survey to all
CRNAs (Appendix A). The IANA distributed the survey to all CRNA members by means of an
email LISTSERV. A web link in the email directed the study participant to the anonymous
online Qualtrics survey. The email template used for survey dissemination by the IANA can be
found in Appendix B.
Test-retest reliability was conducted using a subgroup of CRNAs who volunteered to
retake the survey by providing their email address to determine the reliability of the investigatordeveloped online survey. An email with the survey retest link was sent to all volunteers and a
reminder email was sent two weeks later. A total of 44 CRNA volunteers responded, however
only 28 CRNAs completed the retest survey.

NEOSTIGMINE

19

Instrument
The instrument included brief demographic questions and an investigator-developed
online survey that examined the factors that are considered by anesthesia providers when using
neostigmine as a reversal agent for NMDR such as the age, gender, and weight of patients among
others (Appendix C). The survey questions were related to neostigmine administration practices
among CRNAs. The demographic questions of the survey included years of experience,
education level, type of institution and practice type (academic or non-academic). Face validity
of the survey tool was established through the review of the survey questions by ten content
experts including CRNAs and attending anesthesiologists. Content validity was established
through a comprehensive literature review on the content domains of neostigmine use.
Reliability of the survey was established using test-retest reliability testing using Pearson's r
correlation statistics. A Pearson's r value of .70 or greater indicates adequate reliability of the
online survey. The reliability of the survey was established by sending the survey twice at oneweek intervals to only those participants who volunteered to complete the test-retest.
Human Subjects Protection
Training of Research Personnel on Human Subject Protections was completed May 19,
2015. The researcher of this study completed the following Collaboratve Institutional Training
Initiative (CITI) courses: CITI Health Information Privacy and Security (HIPS) for students,
Responsible Conduct of Research, and Students – Class Projects. Approval was received from
the DePaul IRB on November 23, 2015 (Appendix F).
The study survey was distributed to CRNA members of the IANA via an email from the
IANA. Informed consent was implicit through volunatary completion of the survey. Survey
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responses were collected anonimously via Qualtrics and no IP addesses were associated with the
collected surveys. Data will be destroyed three years after study completion.
Analysis
Descriptive statistics were used to describe the sociodemographics of respondents and the
online responses to the survey. Chi square statistics were performed to examine significant
differences in the factors considered by anesthesia providers when administering neostigmine.
Dichotomous, independent groupings (academic versus non-academic practice type, low level of
years of clinical experience less than five years versus clinical experience of five years or more,
lower level of education with Bachelor’s degree versus higher level of education with Doctoral
degree) of CRNAs were used in the analysis.
Project Design
Assessment. In the assessment phase, an electronic survey was distributed to the target
population to collect demographic data and obtain data related to the current practices of
reversing NDMRs with neostigmine. A Practice protocol for reversing NDMRs using
neostigmine was developed utilizing the study results and the information obtained through the
review of the literature.
Implementation. In the implementation phase, a practice protocol for reversal of
NDMRs using neostigmine will be developed and submitted to the IANA and/or the American
Association of Nurse Anesthetists (AANA) for white paper consideration.
Evaluation. This study leaves the evaluation process of the practice protocol for future
research. A future study could evaluate practice change among the anesthesia providers by
submitting a follow-up survey after implementation of the NDMR reversal protocol. The study
could be expanded to include attending anesthesiologists, anesthesia residents, and SRNAs to
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analyze variance in dosing and administration of neuromuscular blockade reversal amongst the
groups.
Section IV: Findings
Survey Tool
In order to determine content validity the survey was graded by 10 content experts
consisting of six CRNAs and four physician anesthesiologists. The experts comprehensively
graded each of the three categories: “factors for use,” factors for dosing,” and “neuromuscular
monitoring.” In addition, the content experts graded the individual survey questions. The
questions that were graded were specific to the practice of reversing neuromuscular blockade
(Neostigmine Factors Scale) using questions six through 19, and thus excluding questions related
to demographics, provider readiness for practice change, and questions regarding survey
retesting for validity. Each item was graded for clarity, relevance, simplicity, and consistency
using a 10-point Likert-type scale.


Clarity: score of 1 = unclear, score of 10 = very clear



Relevance: score of 1 = not relevant, score of 10 = high relevance



Simplicity: score of 1 = very complex and confusing, score of 10 = simple and
easy to understand



Consistency: score of 1 = inconsistent, score of 10 = high consistency

The results revealed a statistically significant correlation between survey grades by content
experts (r = 0.913, p < 0.000), therefore providing sufficient evidence of survey content validity.
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Table 2. Content Validity
Numbers expressed as Average Score
Domains

Clarity

Relevance

Simplicity

Consistency

1. Factors for
Use

10

8.8

10

9.6

2. Factors for
Dosing

10

9.5

10

9.9

3.
Neuromuscular
monitoring

9.9

9.3

10

10

Questionnaire Q Q Q
Item Number 1
2
3
Domain 1
1
1
Clarity
9. 10 9.
9
5
Relevance
9. 9. 9.
2
8
3
Simplicity
10 10 9.
5
Consistency
10 10 9.
3

Q Q Q Q Q Q
4
5
6
7
8
9
1
1
1
2
2
2
9. 9. 9. 10 9. 9.
9
7
9
8
5
9. 9. 9. 10 9. 9.
5
5
9
5
5
10 10 10 10 9. 9.
9
5
10 10 10 10 10 9.
5

Q1
0
3
10

Q1
1
3
9.6

Q1
2
3
9.6

Q1
3
3
9.3

10

9.7

9.8

9.6

10

9.8

9.8

9.8

10

9.8

9.8

9.8

Clarity: score of 1= unclear up to a score of 10 = very clear question items.
Relevance: score of 1 = not a relevant question items up to a s core of 10 = highly relevant
question items
Simplicity: score of 1 = very complex, confusing question items up to a score 10 = simple, easy
to understand question items
Consistency: score of 1 = inconsistent question items up to a score of 10 = highly consistent
question items
Survey tool reliability. Reliability of the online survey tool was tested using the results
from survey questions six through 19 (Neostigmine Factors Scale). The results revealed the
survey tool was reliable in measuring the opinions of CRNA on the various factors influencing
the use of neostigmine (Cronbach's alpha = 0.711). Additionally, test-retest was also performed
to measure the reliability of the online survey. A total of 44 CRNAs volunteered to complete a
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retest survey, however only 28 participants completed the retest, which contained identical
survey questions to that of the original survey. Using the Pearson intraclass correlation
coefficient test the results of the original survey were correlated with the results of the retest. A
statistically significant correlation was revealed between the two surveys (r = 0.84, p < 0.000),
thereby providing adequate evidence of test-retest reliability.
Descriptive Statistics
Complete survey results were collected from 192 (13.9%) out of 1,384 CRNA members
of the IANA. Survey completion was voluntary and all participants met the inclusion criteria.
Each subject completed an online survey regarding factors used when dosing and administering
neostigmine for reversal of neuromuscular blockade. The majority of the participants had >20
years (n=53, 27.6%) of experience as a CRNA, 23.4% had 0-4 years (n= 45), 22.4% had 5-10
years (n=43), 13.5% had 11-15 years (n=26), 13.0% had 16-20 years (n=25). The majority of
participants held a Masters degree (n=145, 75.5%), 11.5% held a Bachelors degree (n= 22), and
13.0% held a Doctorate degree (n=25). The majority of participants deliver anesthesia in private
hospitals (n=108, 56.3%) followed by public (county) hospitals (n= 53, 27.6%), outpatient
surgical centers (n=29, 15.1%), and Veteran Affairs (V. A.) Hospitals (n=2, 1.0%). Participants
primarily delivered anesthesia in a non-academic facility (n=113, 58.9%) compared to an
academic facility (n=79, 41.1%).
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Table 3. Sociodemographics
Variables
How many years have you been a
Certified Registered Nurse Anesthetist?

What is the highest degree you hold
related to anesthesia?

What type of institution do you
primarily administer anesthesia?

Frequency

Percentage

45

23.4

43
26
25
53
192
22
145
25
192
29

22.4
13.5
13.0
27.6
100.0
11.5
75.5
13.0
100.0
15.1

Public (County)
Hospital

53

27.6

Private Hospital

108

56.3

2

1.0

192

100.0

79

41.1

Non-academic
Total
Agree
Neutral

113
192
151
16

58.9
100.0
78.6
8.3

Disagree
Total
Agree
Neutral
Disagree
Total

25
192
114
51
27
192

13.0
100.0
59.4
26.6
14.1
100.0

0-4 years
5 – 10 years
11 – 15 years
16 – 20 years
> 20 years
Total
Bachelors
Masters
Doctorate
Total
Outpatient Surgical
Center

V.A. Hospital
Total
How would you describe your
anesthesia practice?
I routinely reverse muscle paralysis.

Implementation of a best practice
protocol for the reversal of
neuromuscular blockade using
neostigmine would be beneficial to my
practice.

Academic

Due to the heterogeneous nature of responses to the question, “How many years have you
been a Certified Registered Nurse Anesthetist?,” the variables were grouped together to create
two homogenous variables. The new grouping includes the following variables: 0-10 years
(n=88) and 11- 29 years (n=104) (Table 4). Similarly, variables for the survey question, “What
type of institution do you primarily administer anesthesia?,” were regrouped by combining
variables “V.A Hospital” with “Public (County) Hospital.”. The new grouping includes the
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following variables: outpatient surgical center (n=29), public hospital (n=55), and private
hospital (n=108) (Table 4).
Table 4. Regrouped Variables
Variables
How many years have you
0 – 10 years
been a Certified Registered
11 – 29 years
Nurse Anesthetist?
Total
What type of institution do
Private Hospital
you primarily administer
Public Hospital
anesthesia?
Outpatient Surgical Center
Total

Table 5. Survey Question Frequencies
Variables
I routinely reverse muscle paralysis.

I consider the age of the patient as an
important factor in the administration of
neostigmine.
Overall, I consider the number of muscle
twitches present during train-of-four testing
as an important factor in the administration
of neostigmine.
Overall, I consider the quality of the muscle
twitches during train-of-four testing as an
important factor in the administration of
neostigmine.
I consider twitches with fade during trainof-four testing as an important factor in the
administration of neostigmine.
I consider twitches without fade during
train-of-four testing as an important factor
in the administration of neostigmine.
I consider the time elapsed since the last
dose of neuromuscular blocking agent when
administering neostigmine.
I consider increasing the dose of
neostigmine when the twitches have fade in
train-of-four testing.
I consider decreasing the dose of

Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree

Frequency
88
104
192
108
55
29
192

Frequency
151
16
25
192
56
56
80
192
152
18
22
192
158
18
16
192
146
30
16
192
114
51
27
192
168
10
14
192
105
41
46
192
89

Percentage
45.8
54.2
100
56.3
28.6
15.1
100

Percentage
78.6
8.3
13.0
100.0
29.2
29.2
41.7
100.0
79.2
9.4
11.5
100.0
82.3
9.4
8.3
100.0
76.0
15.6
8.3
100.0
59.4
26.6
14.1
100.0
87.5
5.2
7.3
100.0
54.7
21.4
24.0
100.0
46.4

M

SD

2.66

0.699

1.88

0.834

2.68

0.671

2.74

0.601

2.68

0.622

2.45

0.729

2.80

0.553

2.31

0.834
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neostigmine when the twitches have no fade
in train-of-four testing.
Overall, I consider the patient body mass
index as an important factor for dosing of
neostigmine.
I routinely use subjective neuromuscular
monitoring (i.e. Train-of-four, Tetanus) to
assess patient readiness for reversal with
neostigmine.
I routinely use train-of-four nerve
monitoring to assess patient readiness for
reversal with neostigmine.
I routinely use tetanus nerve monitoring to
assess patient readiness for reversal with
neostigmine.
I routinely use objective neuromuscular
monitoring (i.e. TOF Watch) to assess
patient readiness for reversal with
neostigmine.
Implementation of a best practice protocol
for the reversal of neuromuscular blockade
using neostigmine would be beneficial to
my practice.

Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total
Agree
Neutral
Disagree
Total

50
53
192
72
54
66
192
165
14
13
192
167
14
11
192
83
49
60
192
91
38
63
192
114
51
27
192

26.0
27.6
100.0
37.5
28.1
34.4
100.0
85.9
7.3
6.8
100.0
87.0
7.3
5.7
100.0
43.2
25.5
31.3
100.0
47.4
19.8
32.8
100.0
59.4
26.6
14.1
100.0

2.19

0.841

2.03

0.849

2.79

0.549

2.81

0.518

2.12

0.857

2.15

0.886

2.45

0.729

The body of the survey inquired if CRNAs “agree,” are “neutral,” or “disagree” with
specific factors relating to the dosing and administration of neostigmine, and monitoring of
neuromuscular blockade status to assess readiness for reversal. Factors considered by CRNAs
were defined as those questions having greater than 50% of the CRNAs selecting “agree.”
Factors not considered by CRNAs are those with less than 50% of the CRNAs selecting “agree.”
Factors considered by CRNAs include: number of muscle twitches present during train-of-four
testing (agree=152, 79.2%; neutral=18, 9.4%; disagree=22,11.5%), quality of muscle twitches
present during train-of-four testing (agree=158, 82.3%; neutral=18, 9.4%; disagree=16, 8.3%),
twitches with fade (agree=146, 76.0%; neutral=30, 15.6%; disagree=16, 8.3%), twitches without
fade (agree=114, 59.4%; neutral=51, 26.6%; disagree= 27, 14.1%), time elapsed since the last
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dose of NMBA (agree=168, 87.5; neutral=10, 5.2%; disagree=14, 7.3%). A factor considered by
CRNAs was identified as increasing the dose of neostigmine when the twitches have fade
(agree=105, 54.7%; neutral= 41, 21.4%; disagree= 46, 24.0). Neuromuscular monitoring used
by CRNAs when assessing patient readiness for reversal includes routine use of subjective
neuromuscular monitoring (agree=165, 85.9%; neutral=14, 7.3; disagree=13, 6.8%) and routine
use of train-of-four monitoring (agree=167, 87.0%; neutral=14, 7.3%; disagree=11, 5.7%).
Factors not considered by CRNAs include age of the patient (agree=56, 29.2%; neutral=56,
29.2%; disagree=80, 41.7%), patient body mass index (agree=89, 37.5%; neutral=54, 28.1;
disagree=66, 34.4%), decreasing the neostigmine dose when twitches have no fade (agree=89,
46.4%; neutral=50, 26.0%; disagree=53, 27.6%), routine use of tetanus nerve monitoring
(agree=83, 43.2%; neutral=49, 25.5%; disagree=60, 31.3%), and routine use of objective
neuromuscular monitoring (agree=91,47.4%; neutral=38, 19.8%; disagree=63, 32.8%).
Inferential Statistics
A chi-square test was conducted to determine statistically significant associations
between categorical variables in terms of years of CRNA experience, level of education, type of
practice, and institutional setting and patient age when administering neostigmine. No
statistically significant associations were found between patient age and years of CRNA
experience (Χ2 (2, N = 192) = 4.210, p = 0.122) or CRNA level of education (X2 (4, N = 192) =
0.525, p = 0.971) or type of institution CRNA is employed (X2 (4, N = 192) = 4.841, p = 0.304)
or type of practice (X2 (2, N = 192) = 2.648, p = 0.266).
Results from several survey questions were combined to create two variables:
neuromuscular twitch monitoring and subjective nerve monitoring. The neuromuscular twitch
monitoring variable combines all survey questions regarding practitioner clinical decision

NEOSTIGMINE

29

making in regards to twitch count and quality (questions 8, 9, 10, 11, 13, and 14). The subjective
nerve monitoring variable combines survey questions regarding the use of subject nerve
monitoring including train-of four and tetanus (questions 16, 17, and 18).
An independent-samples t-test was conducted to compare years of CRNA experience and
type of practice to neuromuscular twitch monitoring and the use of subjective nerve monitoring
(i.e. TOF, twitch quality). There was no significant difference in the scores for 0-10 years of
CRNA experience (M = 14.76, SD = 3.49) and 11-29 years of CRNA experience (M=15.27,
SD=2.42), t(190) = -1.206, p = 0.229, compared to neuromuscular twitch monitoring practice.
There was no significant difference in the scores for academic practice type (M = 14.93, SD =
3.02) and non-academic practice type (M = 15.11, SD = 2.93), t(190) = -0.409, p = 0.683,
compared to the use of subjective nerve monitoring. There was no significant difference in the
scores for 0 – 10 years of CRNA experience (M = 7.67, SD = 1.31) and 11-29 years of CRNA
experience (M = 7.76, SD = 1.54), t(190) = -0.474, compared to the use of subjective nerve
monitoring. These results suggest that CRNA experience and type of practice are not influential
factors in the practice of twitch interpretation or subjective neuromuscular monitoring practices.
Test-retest Reliability
A total of 44 CRNAs volunteered to complete a retest survey, however only 28
participants completed the retest, which contained identical survey questions to that of the
original survey. Using the Pearson correlation coefficient test the results of the original survey
were correlated with the results of the retest. A statistically significant correlation was revealed
between the two surveys (r = 0.84, p < 0.000), thereby providing adequate evidence of test-retest
reliability.
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Section V: Discussion
This study is the first investigation that assessed the various factors that CRNAs use in
NMB reversal with neostigmine. Moreover, the differences in factors considered by CRNAs
were also examined for statistically significant associations in terms of the years of CRNA

experience, level of education in anesthesia, type of practice, and institutional setting. First, there
were no statistically significant difference between years of CRNA experience and consideration
of patient age when reversing neuromuscular blockade with neostigmine. Second, there was no
statistically significant difference between years of CRNA experience, CRNA level of education,
type or practice and type of institution when compared to the use of neuromuscular twitch
monitoring, and use of subjective nerve monitoring. Overall, no statistically significant
differences were found in the mean score of the factors considered for neostigmine use between
CRNAs in terms of years of experience, types of practice, institutional settings, and levels of
education. These findings reconfirm the discord present in the practice of NMB reversal, which
was noted in previous studies (Naguib et al., 2010; Videira & Vieira, 2011).
This study also assessed the factors considered by CRNAs when dosing and
administrating neostigmine, and monitoring of neuromuscular blockade status to assess readiness
for reversal. Factors reportedly considered by CRNAs when administering neostigmine include:
number and quality of muscle twitches present during train-of-four testing, twitches with fade,
twitches without fade, and time elapsed since the last dose of NDMR. These factors include the
eight most commonly used factors used for reversal of NDMR identified by Videira and Vieira
(2011). One factor considered by CRNAs when dosing neostigmine is increasing the dose of
neostigmine when the TOF demonstrate fade. According to Kopman and Eikermann (2009),
management of a twitch count of four with fade requires an increased dose of neostigmine
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(0.04mg/kg) compared to a twitch count of four without fade (0.02mg/kg). Nerve monitoring
used by CRNAs when assessing patient readiness for reversal includes routine use of subjective
nerve monitoring and routine use of train-of-four monitoring. Anesthesia providers in the US
commonly use subjective nerve monitoring (includes train-of-four-monitoring) (Naguib et al.,
2010). Factors not commonly used by CRNAs included age of the patient, patient body mass
index, decreasing neostigmine dose when twitches have no fade, routine use of tetanus nerve
monitoring, and routine use of objective neuromuscular monitoring.
This study defined factors used by CRNAs when deciding to reverse NMB as those
having a percentile greater than 50%, however there was significant disagreement amongst
CRNAs regarding these factors. The results of this study duplicate the studies by; Duvalestin,
Cunin, Plaud, and Maison (2008), Gray & Wilson (1959), Naguib et al. (2010), and Videira and
Vieira (2011) which identified a large variation in the practice of dosing and administering
neostigmine amongst anesthesia providers. Evidenced by the overwhelming lack of statically
significant data this study highlights the dissonance present amongst anesthesia providers in the
dosing and administration practices of neostigmine. With residual NMB affecting upwards of
40% of post-operative patients who received intra-operative neuromuscular blocking agents, it is
evident that the current practice of neostigmine use is inadequate (Murphy & Brull, 2010). A set
of universally excepted evidence-practice guidelines for the reversal of NMB with neostigmine is
necessary to aid anesthesia providers in safe and consistent NMB reversal practices.
Residual NMB occurs far too often in post-operative patients and results in an increased
morbidity and mortality. As seen in the results of this study, the current practice of reversing
muscle paralysis remains unstandardized resulting in a large variation in the practice of dosing
and administering neostigmine, and NMB status when reversing with neostigmine. This
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unstandardized approach promotes residual NMB and endangers patient safety and should be
addressed immediately.
Limitations
Limitations of the study were identified. First, the survey tool did not include a gender
differentiation question. Analyzing variances between genders is typically standard, albeit there
is no difference in the clinical training or didactic course work between male and female nurse
anesthetists, therefore it is unlikely gender has a role in dosing and administering neostigmine.
Second, this survey had a small population and was restricted only to CRNA members of IANA;
excluded were attending anesthesiologists, anesthesia residents, and SRNAs, thereby limiting
generalizability of study findings to the overall anesthesia provider population. Future studies on
this topic could include these anesthesia providers populations. Third, the study focused only on
the most commonly used cholinesterase inhibitor, neostigmine; results must be interpreted with
caution as there are other agents being used in the clinical setting.
Recommendations
Development of a universally accepted evidence-based practice protocol for the reversal
of NMB using neostigmine is necessary to improve patient safety and reduce post-operative
morbidity and mortally related to residual NMB. The evidence obtained from this study was be
used to develop an evidence-based protocol for the safe reversal of NMB. A protocol
incorporating key factors in the reversal of NMB identified in this study is outlined below. The
investigators of this study plan to submit this protocol to the IANA and/or the AANA for white
paper consideration.
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Evidence-based Guidelines Neuromuscular Blockade Reversal With Neostigmine
TOF

0 – 1 Twitch

2-3 twitches

TOF Ratio

4 Twitches w/ Fade

4 Twitches w/o Fade

TOFR < 0.4

TOFR ≥ 0.4

Neostigmine

Wait on Reversal

Administer 50mcg/kg3

Administer 40 mcg/kg3

Administer 20 mcg/kg3

Timing

N/A

15-30 min before

15-30 min before

15-30 min before

2

extubation

2

extubation

extubation2

Clinical Considerations:
Neostigmine:

Monitoring:



Dose: 20-50 mcg/kg3



Monitoring is a standard of care1



Administer concomitantly with



Objective monitoring is preferred over subjective as

anticholinergic (i.e Glycopyrrolate)11


No reversal recommended for TOFR ≥ 0.9



Obesity9 and increased age10 lengthens
reversal time to TOF ratio ≥ 0.9

it most reliably monitors status of NMB1, 12


The preferred site for peripheral nerve stimulation is
the adductor pollicis13 (ulnar nerve stimulation).



Do not rely on clinical signs/test (i.e. headlift, hand
grasp, eye opening) as they do not accurately
represent status of neuromuscular recovery4,5,6,7

1

(Brull & Murphy, 2010), 2(Murphy, 2006), 3(Kopman & Eikermann, 2009), 4(Eikermann, Groeben, Hussing, &
Peters, 2003), 5(Hayes, Mirakhur, Breslin, Reid, & McCourt, 2001), 6(Fruergaard, Mogensen, Berg, & El Mahdy,
1998), 7(Mogensen & Claudius, 2010), 8(Buder, 2010), 9(Suzuki, Masaki, Ogawa, 2006), 10(Bevan, et al., 1999),
11
(Butterworth, Mackey, & Wasnick, 2013a), 12(Murphy et al., 2008), 13(Thilen et al., 2012)

It is important to note that improvement of the practice of neuromuscular blockade
reversal is not a substitute for interdisciplinary communication. In fact, effective communication
is equally as important as following the evidence-based practice guidelines. There has to be an
exchange of communication between the anesthesia provider and the surgeon to assess postoperative plans, estimated duration to the end of surgery, and whether maintenance of
neuromuscular blockade is required throughout the case. Each of these discussion points has the
potential to affect the neuromuscular blockade plan, and if proper communication does not take
place there is an increased risk of harm to the patient.
Implications for Future Research
This study defers the evaluation process for future research. After initiation of the
evidence-based guidelines for neuromuscular blockade reversal with neostigmine at the
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institutional, state, or national level, evaluation of possible change in practice could take place.
Resubmission of the survey tool (Appendix C) to the same population would allow for
comparisons between neuromuscular block reversal practices pre-EBP protocol and post. In
addition, surveillance of residual neuromuscular blockade incidence rates could assess the effects
of practice change, although this issue is multifactorial and it may be difficult to determine the
cause of any incidence rate changes. Additional follow-up studies could include additional
anesthesia providers including attending anesthesiologists, anesthesia residents, and student
nurse anesthetists. Furthermore, these follow up studies should compare the dosing and
administration practices of neostigmine between attending anesthesiologists, anesthesia residents,
student nurse anesthetists, and CRNAs.
Conclusion
This study described the various factors used by CRNAs when dosing and administering
neostigmine. There are no significant associations in any of these factors with CRNAs'
subgroupings according to their years of anesthesia experience, level of education in anesthesia,
type of practice, and institutional setting. The overall factors used by CRNAs include the
number and quality of muscle twitches present during train-of-four testing, twitches with and
without fade, time elapsed since the last dose of NDMR, increased dosing of neostigmine when
the twitches have fade, and routine use of subjective neuromuscular monitoring, including TOF.
Residual neuromuscular blockade occurs far too often in post-operative patients and
results in an increased morbidity and mortality. The current practice of reversing muscle
paralysis is not standardized, resulting in a large variation in the neostigimine dosing practice,
and evaluation of NMB status when reversing with neostigmine. This nonstandardized approach
promotes residual NMB and endangers patient safety. This study presented a set of evidence-
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based guidelines with the goal of standardizing NMB reversal. The standardization of practices
related NMB reversal will improve patient safety and reduce the incidence of residual
neuromuscular blockade.
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Table 1. Synthesis of the Adverse Effects of Residual Neuromuscular Blockade
Authors & Year

Purpose

Design

Sample/Population

(Debaene, Plaud, Dilly,
& Donati, 2003)

Evaluate incidence of
residual paralysis
(TOF Ratio < 0.9) in
the PACU after a
single intubating dose
of an intermediateacting NDMR is
administered at a
dosage twice the
ED95.

-Nonrandomized,
observational
study.
-Anesthetic
management was
provider specific.
-Groups:
-Vecuronium
-Rocuronium
-Atracurium
-Nonrandomized,
controlled Study.
-Study intervals:
TOF 0.7, 0.8,
and >0.9

-526 patients

(Cedborg et al., 2014)

(Hayes, Mirakhur,
Breslin, Reid, &
McCourt, 2001)

(Murphy et al., 2008)

Evaluate the effects
of partial NMB on
pharyngeal function,
coordination of
breathing and
swallowing, and
airway protection in
the elderly.
Compare incidence
of postoperative
residual NMB in
patients entering the
PACU after use of
intermediate-acting
NMBDs.

1) Compare
effectiveness of
objective

-Randomized,
controlled study
-Provider
unaware that
patient is in
study.
-Four Groups:
-Control
-Vecuronium
-Atracurium
-Rocuronium
-Data collected
on randomized
days.
-Randomized,
controlled, single
blind Study

-No mention of IRB or
ethics committee
approval.

Study Group: 17
volunteers over 65 years
old
Control Group: 6
volunteers over 65 years
old
-Local Ethics Board
Approved.
-160 patients
-LRB Approved
-Written and informed
consent obtained

-185 patients undergoing
elective surgery requiring
intraop NMB.

Statistical
Analysis
-Probability
values were
used to reject
null
hypothesizes.
-No other
statistical
calculations
were reported.

Findings
-Patients with a TOF ratio <0.7: 16%
-Patients with a TOF ratio < 0.9: 45%
-10% of patients had a TOF ratio <0.7 2
hours or more after administration of MR.
-Traditional clinical tests (head lift, tongue
depressor) and manual assessment of twitch
fade demonstrated a poor sensitivity to detect
residual block (11-14%).

-ANOVA
-Generalized
linear model
-Wilcoxon test
-MannWhitney U test

-Positive correlation between partial NMB
and increased pharyngeal dysfunction.
-No correlation between partial NMB and
coordination of breathing and swallowing.

-One-way
ANOVA
-KruskalWallis test
-Chi-squared
Test

-A large proportion of patients entering the
PACU, whom have received intermediateacting NMBDs, have a TOF ratio < 0.8.

-One-sided
Chi squared
test

-Intraoperative management of NMB did not
differ significantly.
-No statistical significance of the time from
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(Sundman et al., 2000)

(Suzuki, Masaki, &
Ogawa, 2006)

neuromuscular
monitoring on the
incidence of
postoperative residual
NMB with qualitative
monitoring.
2) Effect of
intraoperative
objective monitoring
on postop hypoxemia
and airway
obstruction.
1) Evaluate
swallowing using
fluoroscopy to record
and understand the
mechanism behind
pharyngeal
dysfunction during
partial NMB.
2) Evaluate the
effects of Atracurium
on pharyngeal
function.

Compare reversal of
vecuronium by
neostigmine in
normal weight,
overweight, and
obese female
patients.

-Groups:
Acceleromyography group
-Conventional
TOF Group
(control).
-Standardized
anesthetic
management

-IRB approved
-Written and informed
consent obtained

-Fisher exact
probability test
-MannWhitney U test
-Spearman
Rank
Correlation
Coefficient

administration of reversal to extubation.
-A significantly higher incidence of TOF
ratio <0.7 occurred in the conventional
group.

-Nonrandomized,
controlled Study.
-A total of 444
swallows
analyzed.
-Counted each
swallow as 1
data point &
Compared TOF
ratio (0.6, 0.7,
0.8, > 0.9) to
area of
penetration
(pharynx, larynx,
or bolus
remained in
mouth)
Nonrandomized,
controlled study.
-Three Groups:
-Normal
Weight
-Overweight
-Obese
-Normal weight
group is control.

Sample Size: 20 healthy
volunteers (12 men, 8
women)
-LRB approved

-Regression
-T-test
-Wilcoxon
signed rank
test

-Partial NMB by Atracurium is associated
with an increased incidence of misdirected
swallowing.
-The MOA of pharyngeal dysfunction was
identified as a delayed initiation of the
swallowing reflex, impaired function of
pharyngeal muscles, and impairment of
coordination.
-The majority of misdirected boluses
penetrated the laryngeal inlet.

-45 female patients.
-ASA physical status I or
II
-Age 27-57 years old
-Elective gynecologic
surgery.
-Approval by Hospital
Ethics Committee on
Human Rights in
Research.

-ANOVA
-Bonferroni
post hoc test

-When using RBW to dose vecuronium,
recovery to a TOF ratio of 0.9 is slow in
overweight and obese (female) patient
population.
-Time to TOF ratio of 0.9:
- Obese: 25.9 minutes
-Overweight: 14.6 minutes
-Normal Weight: 6.9 minutes
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-Vecuronium
dosing using real
body weight
(RBW).
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Appendix A. Letter to IANA Administrator
Dear IANA Administrator,
My name is Kyle Mayer and I am a Nurse Anesthesia Trainee from DePaul University and
NorthShore University School of Nurse Anesthesia. I am conducting a research study on the
current practice of dosing and administration of the neuromuscular blockade reversal agent,
neostigmine. I am writing to request an email containing a web link to the survey be emailed to
all CRNA members of the IANA.
Participation in the study is voluntary. All responses are anonymous and IP addresses will not be
tracked.
I have attached the email message with the link to the survey. The survey is now available and
the survey invitation email can be distributed at your soonest convenience. Please contact me
with any questions or concerns.
Thank you very much.
Sincerely,
Kyle Mayer, BSN, RN, NAT
DePaul University
NorthShore University – School of Nurse Anesthesia
mayerkyle427@hotmail.com
Attachment: (See Appendix B)

NEOSTIGMINE
Appendix B. Email Template for Survey Dissemination
Dear Illinois CRNA,
My name is Kyle Mayer and I am a Nurse Anesthesia Trainee from DePaul University. I am
writing to invite you to participate in my research study regarding the current practice of
neuromuscular blockade reversal dosing and administration. This study is only available to
members of the Illinois Association of Nurse Anesthetists.
All responses are anonymous and IP addresses will not be tracked. Study participation is
completely voluntary, and it will take about 5 minutes of your time to complete the survey. If
you would like further details regarding this study, I have attached a study information sheet.
If you'd like to participate in this study please click the following link –
http://depaul.qualtrics.com/SE/?SID=SVcPatJOquqcRYRtr
Thank you very much.
Sincerely,
Kyle Mayer, BSN, RN, NAT
DePaul University
mayerkyle427@hotmail.com
Attachment: Study Information Sheet
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Appendix C. Survey of the Current Practice of Muscle Paralysis Management and Reversal

1. You are invited to participate in a web-based online survey on the development of practice
guidelines for the reversal of neuromuscular blockade using neostigmine. Your participation
in this survey is voluntary. You may refuse to take part in the research or exit the survey at
any time without penalty. You are free to decline to answer any particular question you do
not wish to answer for any reason.
This online survey will not collect identifying information such as your name, email
address, or IP address; therefore, your responses will remain anonymous. If you agree to
participate in the second follow-up survey, we will ask for your email address in order to
send you another survey. In this case your responses will not be anonymous, but we will
keep them confidential.
Consent: If you would like to take part in this brief survey click “Accept.” If you choose
to not participate in this survey click “Decline,” and close your browser window.
 Accept

 Decline

2. How many years have you been a Certified Registered Nurse Anesthetist?
0-4

5-10

11-15

16-20

>20

3. What is the highest degree you hold related to anesthesia?
Bachelors

Masters

Doctorate

4. What type of institution do you primarily administer anesthesia?
Outpatient Surgical Center

Public (County) Hospital Private Hospital

VA Hospital

5. How would you describe your anesthesia practice?
Academic

Non-academic

6. I routinely reverse muscle paralysis.
Disagree

Neutral

Agree

7. I consider the age of the patient as an important factor in the administration of neostigmine.
Disagree

Neutral

Agree

8. Overall, I consider the number of muscle twitches present during train-of-four testing as an
important factor in the administration of neostigmine.
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Disagree

Neutral

Agree

9. Overall, I consider the quality of the muscle twitches during train-of-four testing as an
important factor in the administration of neostigmine.
Disagree

Neutral

Agree

10. I consider twitches with fade during train-of-four testing as an important factor in the
administration of neostigmine.
Disagree

Neutral

Agree

11. I consider twitches without fade during train-of-four testing as an important factor in the
administration of neostigmine.
Disagree

Neutral

Agree

12. I consider the time elapsed since the last dose of neuromuscular blocking agent when
administering neostigmine.
Disagree
Neutral
Agree
13. I consider increasing the dose of neostigmine when the twitches have fade in train-of-four
testing.
Disagree

Neutral

Agree

14. I consider decreasing the dose of neostigmine when the twitches have no fade in train-offour testing.
Disagree

Neutral

Agree

15. Overall, I consider the patient body mass index as an important factor for dosing of
neostigmine.
Disagree

Neutral

Agree

16. I routinely use subjective neuromuscular monitoring (i.e. Train-of-four, Tetanus) to assess
patient readiness for reversal with neostigmine.
Disagree

Neutral

Agree

17. I routinely use train-of-four nerve monitoring to assess patient readiness for reversal with
neostigmine.
Disagree

Neutral

Agree
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18. I routinely use tetanus nerve monitoring to assess patient readiness for reversal with
neostigmine.
Disagree
Neutral
Agree
19. I routinely use objective neuromuscular monitoring (i.e. TOF Watch) to assess patient
readiness for reversal with neostigmine.
Disagree

Neutral

Agree

20. Implementation of a best practice protocol for the reversal of neuromuscular blockade using
neostigmine would be beneficial to my practice.
Disagree

Neutral

Agree

****************************New Page****************************
Would you be willing to take the same survey again in 1 week to assess consistency of survey
responses?
YES (Repeat survey link will be sent in 1 week)
If YES, please type your email address:________________________
NO (no repeat survey link will be sent)
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Appendix D. Email Template for Test/Re-test Survey Validity
Dear Illinois CRNA,
My name is Kyle Mayer and I am a Nurse Anesthesia Trainee from DePaul University. I am
writing you because you recently participated in a research and volunteered to retake a portion of
the survey. As a reminder, the research study is regarding the current practice of neuromuscular
blockade reversal dosing and administration.
Again, all responses are anonymous and IP addresses will not be tracked. Study participation is
completely voluntary; you have the choice to participate in this study or to not. If you'd like to
participate in this follow up survey please click the following link – [weblink to survey].
Thank you very much.
Sincerely,
Kyle Mayer, BSN, RN, NAT
DePaul University
mayerkyle427@hotmail.com

NEOSTIGMINE
Appendix E. SLP Committee Members
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Appendix F. IRB Approval Letter
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